Status
Conditions
Treatments
About
The purpose of this global multicenter confirmatory study is to evaluate the clinical efficacy and safety of Quantum-Inspired Intervention (QII), a novel non-invasive neurodevelopmental protocol, in children diagnosed with Autism Spectrum Disorder (ASD).
Autism Spectrum Disorder involves complex neurodevelopmental dynamics characterized by challenges in emotional regulation and adaptive functioning. Existing clinical paradigms primarily rely on pharmaceuticals for secondary symptom control or behavioral methods aimed at external behavioral modification, while interventions targeting core functional shifts remain limited. Grounded in a quantum-inspired conceptual framework aimed at addressing foundational adaptive processing, QII integrates AI-enabled, fine-grained characterization of each child's needs with a proprietary quantum-inspired intervention protocol delivered by trained practitioners. While fully elucidating the fundamental mechanisms will require extended scientific timelines, the urgent needs of individuals and families make confirming tangible, real-world functional efficacy the paramount priority.
Preliminary case reports of the QII protocol observed encouraging signals in emotional stabilization and spontaneous communication. Building on these initial findings, this study systematically evaluates the efficacy of QII at scale in an expanded, multicenter cohort. Eligible participants will be randomized to receive either the standardized QII protocol over a defined period or a waitlist control, with the waitlist control arm offered QII following completion of the primary analysis. The primary endpoint evaluates improvement in the autism-related symptom or functional difficulty identified as the primary intervention target at baseline, as measured by the Clinical Global Impression-Improvement (CGI-I) scale; changes in irritability and behavioral dysregulation, as measured by the Aberrant Behavior Checklist-Irritability Subscale (ABC-I), are evaluated as a secondary endpoint.All efficacy endpoints are assessed by independent clinicians blinded to group allocation. Caregivers may report any adverse event or safety concern at any time and may request to stop the intervention at any time; adverse events are also recorded at scheduled study assessments.
Full description
STUDY RATIONALE AND OBJECTIVES Autism Spectrum Disorder (ASD) involves complex neurodevelopmental dynamics characterized by challenges in emotional regulation and adaptive functioning. Existing clinical paradigms primarily rely on pharmaceuticals for secondary symptom control or behavioral methods aimed at external behavioral modification, while interventions targeting core functional shifts remain limited.
While fully elucidating the fundamental mechanisms will require extended scientific timelines, the urgent needs of individuals and families make confirming tangible, real-world functional efficacy the paramount priority. This global multicenter confirmatory study is designed to evaluate the clinical efficacy and safety of Quantum-Inspired Intervention (QII), a novel non-invasive neurodevelopmental protocol, in children diagnosed with Autism Spectrum Disorder (ASD).
CONCEPTUAL FRAMEWORK AND OPERATIONAL WORKFLOW Grounded in a quantum-inspired conceptual framework aimed at addressing foundational adaptive processing rather than superficial behavior management, QII integrates AI-enabled, fine-grained characterization of each child's needs with a proprietary quantum-inspired intervention protocol delivered by trained practitioners.
All randomized participants, in both the experimental and waitlist control arms, complete the identical workflow described below; the QII protocol itself is delivered only to the experimental arm during the study period, and to the waitlist control arm following completion of the primary analysis.
The procedural workflow and operational division of responsibilities across the trial follow a standardized five-stage cycle:
STUDY TIMELINE AND CLINICAL PHASING
The overall clinical trial is conducted over a comprehensive 12-month operational timeline across participating sites, encompassing multicenter patient recruitment, standardized intervention delivery, blinded endpoint assessment, and statistical data lock:
OUTCOME MEASURES AND ENDPOINT SPECIFICATIONS
The trial employs validated, objective clinical instruments to evaluate tangible gains in adaptive communication, emotional self-regulation, and overall clinical response:
Primary Outcome
Title:Clinical Global Impression-Improvement (CGI-I) Score for the Primary Intervention Target Description:CGI-I rated by a blinded independent clinician on a 7-point scale (1 = very much improved; 7 = very much worse), assessing improvement relative to baseline in the autism-related symptom or functional difficulty identified as the primary intervention target at baseline.
Time Frame:End of the 3-month intervention period
Secondary Outcome
Title:Change from Baseline in Aberrant Behavior Checklist-Irritability Subscale (ABC-I) Score Description:ABC-I subscale (15 items; score range 0-45; higher scores indicate greater irritability), completed by caregivers under the administration of a blinded assessor.
Time Frame:Baseline and end of the 3-month intervention period
ETHICAL OVERSIGHT AND DATA GOVERNANCE The trial is conducted in full compliance with Good Clinical Practice (GCP) guidelines and international ethical standards for pediatric research. An independent Data Monitoring Committee (DMC) conducts scheduled reviews of safety and data integrity. All digital interactions, AI-supported data processing, and clinical records are handled via secure, encrypted, HIPAA-compliant cloud architectures.
STUDY DESIGN A randomized, parallel-group design evaluating the efficacy and safety of the Quantum-Inspired Intervention (QII) protocol compared to a waitlist control arm over a 3-month intervention period. The target sample size of 80 participants (40 per arm) provides 90% power to detect a difference in CGI-I response rates (defined as a CGI-I score of 1 or 2) of 40% in the QII arm versus 10% in the waitlist control arm, using a two-sided test at a significance level of 0.05, and maintains greater than 85% power allowing for a 10% dropout rate.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
80 participants in 2 patient groups
Loading...
Central trial contact
Elysia Zixing Wang, BS; Sarah Yujia Wang, Master in Applied Math
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal